Bayer lost a fifth of its market value at one point Monday, after the German pharmaceutical and agricultural group said it had ended a late-stage test for the anti-thrombotic drug asundexian due to a lack of efficacy.
Read Full Story
- Outside the Box: Here’s how to know if your mutual fund sees ESG investing clearly - December 9, 2023
- The Fed: Fed will try to ‘Keep calm and carry on’ amidst talk of steep rate cuts and recession - December 9, 2023
- The Number One: This family just bumped Walmart’s Waltons as the richest in the world - December 9, 2023